Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease.

Journal article

Cilomilast (Ariflo), a new oral phosphodiesterase-4 selective inhibitor, improves lung function in chronic obstructive pulmonary disease (COPD). We have evaluated its antiinflammatory effects in 59 patients with COPD randomized to receive cilomilast, 15 mg two times a day, or placebo for 12 weeks. Induced sputum differential cell counts were obtained at baseline and at five further visits. Interleukin-8 and neutrophil elastase were measured in sputum supernatant. Bronchial biopsies obtained a...

Expand abstract

Authors: Gamble, E; Grootendorst, D; Brightling, C; Troy, S; Qiu, Y

• Journal: American journal of respiratory and critical care medicine
• Volume: 168
• Issue: 8
• Pages: 976-982
• Publication date: 2003-10-01
• DOI: 10.1164/rccm.200212-1490oc
• EISSN: 1535-4970
• ISSN: 1073-449X
• Language: English
• Keywords: Nitriles; Anti-Inflammatory Agents; 3',5'-Cyclic-AMP Phosphodiesterases; Double-Blind Method; Aged; Adult; Biopsy; Pulmonary Disease, Chronic Obstructive; Bronchodilator Agents; Sputum; Aged, 80 and over; Leukocyte Elastase; Antigens, CD; Middle Aged; Forced Expiratory Volume; Treatment Outcome; Cyclohexanecarboxylic Acids; Cyclic Nucleotide Phosphodiesterases, Type 4; Antigens, Differentiation, Myelomonocytic; CD8-Positive T-Lymphocytes; Male; Female; Humans; Interleukin-8; Leukocyte Count; Phosphodiesterase Inhibitors; CD4-Positive T-Lymphocytes; Carboxylic Acids